Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 5;8(4):365-368.
doi: 10.1002/iju5.70041. eCollection 2025 Jul.

Leuprorelin-Induced Thrombocytopenia Successfully Treated With Surgical Resection of the Injection Site

Affiliations

Leuprorelin-Induced Thrombocytopenia Successfully Treated With Surgical Resection of the Injection Site

Ryota Mori et al. IJU Case Rep. .

Abstract

Introduction: Drug-induced thrombocytopenia (DITP) can be caused by many kinds of drugs. Its treatment generally involves discontinuation of the responsible drug.

Case presentation: A 70-year-old man received a subcutaneous injection of long-acting (24-week) leuprorelin depot as androgen deprivation therapy for prostate cancer. Four days after the injection, he presented with gingival bleeding and his platelet count was remarkably decreased (< 1000/μL). There was no sign of malignancy but the presence of megakaryocytes on bone-marrow examinations. Considering immune and/or DITP, he started immunoglobulin and steroid therapy while stopping all suspected medications. However, even a month later, his platelet count did not recover with the need for frequent platelet transfusions. Therefore, he eventually underwent surgical resection of the leuprorelin injection site. After the surgery, his platelet count drastically recovered and platelet transfusion became unnecessary.

Conclusion: We report a case of leuprorelin-induced thrombocytopenia that was successfully treated with surgical resection of the injection site.

Keywords: androgen deprivation therapy; drug‐induced thrombocytopenia; gonadotropin‐releasing hormone analog; leuprorelin; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
(A) Preoperative computed tomography identified the leuprorelin injection site as increased adipose tissue density (arrow, 30 × 15 mm). (B) The leuprorelin injection site was also palpable as subcutaneous induration. (The red dashed line shows the planned area for resection, while the red solid line indicates the planned line for skin incision.) (C) The subcutaneous adipose tissue of the leuprorelin injection site was completely excised with a sufficient surgical margin until the anterior rectus sheath was exposed (45 × 30 mm). (D) Macroscopic image of the excised subcutaneous tissue. (E) Microscopic image of the specimen (hematoxylin and eosin stain) showed fibrosis admixed with degenerated adipose cells and histiocytes with foreign material.
FIGURE 2
FIGURE 2
Clinical course including changes in platelet count and doses of prednisolone.

Similar articles

References

    1. Maneerot T., Saelue P., and Sangiemchoey A., “Phenytoin‐Induced Severe Thrombocytopenia: A Case Report,” Cureus 16 (2024): e60669. - PMC - PubMed
    1. Marini I., Uzun G., Jamal K., and Bakchoul T., “Treatment of Drug‐Induced Immune Thrombocytopenias,” Haematologica 107 (2022): 1264–1277. - PMC - PubMed
    1. Bakchoul T. and Marini I., “Drug‐Associated Thrombocytopenia,” Hematology. American Society of Hematology. Education Program 2018 (2018): 576–583. - PMC - PubMed
    1. Merseburger A. S. and Roesch M. C., “Advanced Delivery of Leuprorelin Acetate for the Treatment of Prostatic Cancer,” Expert Review of Anticancer Therapy 22 (2022): 703–715. - PubMed
    1. Aster R. H., Curtis B. R., McFarland J. G., and Bougie D. W., “Drug‐Induced Immune Thrombocytopenia: Pathogenesis, Diagnosis, and Management,” Journal of Thrombosis and Haemostasis 7, no. 6 (2009): 911–918. - PMC - PubMed

LinkOut - more resources